Unterstützte Projekte

  • Physico-chemical properties of mixed micelles and vesicles composed of phospholipids and surfactants. Prof. Dr. A. Blume, University of Halle-Wittenberg/Germany
  • Oral bioavailability screening of new drug compounds: comparison of the phospholipid vesicle based model with Caco-2 model. Prof. Dr. M. Brandl, University of Tromsø in cooperation with Prof. Dr. G. Fricker, University of Heidelberg/Germany
  • Phospholipid/Tetraether-lipid based liposomes for controlled drug delivery. Prof. Dr. G. Fricker, University of Heidelberg/Germany
  • Study of oral bioavailability of Mebudipine and Dibudipine upon administration in novel PhytoSolve formulation in rats. Dr. F. Keyhanfar, University of Teheran/Iran
  • Hydrogenated Phospholipids as anti-metastatic agents. Prof. Dr. U. Massing, Clinic for Tumor Biology Freiburg/Germany
  • Phosphatidylcholines in anticancer drug delivery – mere innocent bystanders? Dr. G. Puetz, University Hospital Freiburg/Germany
  • Anti-Helicobacter pylori IgY targeting combination. Dr. Z. Quanming, The Third Military Medical University, Chongqing/People’s Republic of China
  • A lipid based drug delivery system for CNS applications. Dr. V. Reichel, University of Heidelberg/Germany
  • Using liposomes as carriers for plant derived polyphenolic antibacterial compounds. Dr. S. Ristori, University of Florence/Italy
  • The effect of foreign molecules on the physico-chemical properties of phospholipid bilayer membranes (liposomes). New applications of phospholipids for in-vitro toxicity studies of chemicals. Prof. Dr. F. Scholz, University of Greifswald/Germany
  • Caco-2 cell studies on lipid-mediated intestinal adsorption of active substances. Prof. Dr. R. Schubert, University of Freiburg/Germany
  • Liposomal delivery of curcumin and Curcuma extract as the anti-inflammatory and anticancer agents intended for vaginal therapy, Prof. Dr. N. Skalko-Basnet, University of Tromsø/Norway
  • Phospholipid complexation as toolbox for improving anti-inflammatory treatment. Dr. M. Tawab, Zentrallaboratorium Deutscher Apotheker GmbH, Eschborn/Germany
  • Mechanistic Action and Adverse Event of therapy with delayed release - Phosphatidylcholine in a genetic mouse model of ulcerative colitis. Prof. Dr. W. Stremmel, University Clinic Heidelberg/Germany
  • Investigation of the retention of lipophilic drug compounds within liposomal drug carriers. Dr. S. Hupfeld, Oslo University College/Norway, Prof. Dr. M. Brandl, University of Southern Denmark/Odense/Denmark
  • Phospholipid/Tetraetherlipid based liposomes for oral administration of Hepatitis B Virus-derived lipopeptides for hepatocyte-specific drug delivery, Prof. Dr. G. Fricker, Prof. Dr. W. Mier, Prof. Dr. S. Urban, University Heidelberg/Germany
  • Investigation of cochleate formulation and cochleate-cell membrane interactions, Prof. Dr. A. Fahr, University Jena/Germany
  • Distribution of phospholipid based Drug carriers into organs and tumors – monitoring by mass spectrometry imaging. Prof. Dr. C. Hopf, University Mannheim/Germany
  • Studies on monoacyl lecithin complexes with poorly soluble drugs – which compounds benefit particular from a dissolution enhancement regarding improved oral bioavailability? Prof. Dr. M. Kuentz, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz/Switzerland
  • Phospholipid-Based Solid Dispersions for Enhanced Oral Absorption of Poorly Soluble Drugs. Prof. Dr. A. Bauer-Brandl, University of Southern Denmark/Odense/Denmark
  • Interactions of the tumour-targeting vector peptide pHLIP with phospholipids. Prof. Dr. S. Keller, University Kaiserslautern/Germany
  • Inhibitory effect of phospholipids on the efflux transporter P-glycoprotein. Prof. Dr. R. Schubert, University Freiburg/Germany
  • Impact of phospholipid oxidation on biophysical properties of membranes. Prof. Dr. M. Tanaka, University Heidelberg/Germany
  • Interaction of phospholipids with the skin in human subjects. Dr. M. Lane, University London/United Kingdom
  • Oral anticancer-indirubins: Solubility enhancement, permeability and bioavailability assessment of SMEDDS formulations. Dr. A. Mahringer, University Heidelberg/Germany
  • The investigation of the interaction of liposomal formulations containing poorly water soluble drugs with human plasma. Prof. Dr. A. Fahr, University Jena/Germany
  • Elucidating the use of lyso-phospholipids in oral self-nanoemulsifying drug delivery systems. Prof. Dr. A. Müllertz, Copenhagen/Denmark
  • In vivo detoxification of alcohol using phospholipids supported bioreactors. Prof. Dr. J.-Ch. Leroux, ETH Zurich/Switzerland
  • Assessment and better prediction of acute hypersensitivity and complement involvement upon administering liposomal drug products to human subjects. Dr. J. Metselaar, University Twente/The Netherlands/Prof. Dr. J. Szebeni, Semmelweis University/Budapest/Hungary
  • Design of well-defined liposomes to target tumor-associated M2 macrophages. Dr. J. Prakash, University Twente/Utrecht/The Netherlands
  • Improving treatment of pediatric sarcomas through targeted liposomal drug delivery. Dr. M. Bernasconi, University Children’s Hospital Zurich/Switzerland
  • Development of NLCs and nanoemulsions with monoacyl-phospholipids and investigation of their skin penetration and influence on skin barrier structure in vitro and in vivo. Prof. Dr. C. Valenta, University Wien/Austria
  • Inhibition of Akt by Polyunsaturated Phosphatidylcholine – a Novel Approach for Anti-Cancer Therapy. Dr. A Köberle, University Jena/Germany
  • Phospholipid microemulsions for the dermal application of proteins: Prediction of in-vivo skin tolerability with full-thickness human skin equivalent. PD Dr. R. Scherließ, University Kiel/Germany
  • Phospholipids as functional excipient in solid oral dosage forms. Prof. Dr. R. Bodmeier, FU Berlin/Germany
  • Physicochemical characterization of natural phospholipid excipients and development of colloidal carrier systems for active substances (micro-emulsions) on the basis of phospholipids for dermal application. Prof. Dr. R. Neubert, University Halle (Saale)/Germany and Prof. Dr. G. Brezesinski, Max-Planck-Institute for Colloid and Interface Research/Potsdam/Germany
  • Treatment and diagnosis of early gastric Cancer with lipid based formulated Hypericin by applying photodynamic therapy. Dr. F. Helm, University Heidelberg/Germany
  • A Phospholipid-Functionalized Calcium Carbonate Based Drug Delivery System to Improve the Bioavailability of Poorly Water-Soluble Drugs. Prof. Dr. J Huwyler, University Basel/Switzerland 
  • Phosphatidylserine enriched phospholipids as anti-inflammatory agents. Prof. Dr. K. Mäder, University Halle (Saale)/Germany
  • Phospholipid based liquid-fill formulations for hard capsules. Prof. Dr. Heike Bunjes, University Braunschweig/Germany
  • On-demand amplification of chemotherapy by ultra-fast drug release from plasmonic liposomes. Dr.  Xiuying Li. University of Dallas/USA
  • Establishing a more rational design of thermo-responsive liposomes. Prof. Dr. H. Heerklotz, University Freiburg/Germany
  • Development of a phospholipid-based depot technology for sustained drug release. Prof. Dr. P. Luciani, University Jena/Germany
  • Evaluation of cochleates as parenteral depot formulations. Prof. Dr. J. Kuntsche. University of Southern Denmark/Odense/Denmark
  • Liposomal oral drug delivery: The use of bipolar amphiphiles to stabilize liposomes. Dr. S. Drescher, University Halle/Germany
  • Investigation of liposomal transdermal drug delivery by Raman microscopic imaging in combination with stable isotopic labelling as a new non-invasive modality to study drug penetration. Dr. Ch. Matthaeus, University Jena/Germany
  • Theranostic phospholipid-coated ultrasound contrast agents: response on demand. Dr. K. Kooiman, Erasmus University Medical Center Rotterdam/The Netherlands  
  • Production of liposomes by centrifugation of water in oil emulsions. Prof. Dr. H. Nirschl, Karlsruhe Institute for Technology (KIT)/Germany
  • Synergy-based delivery system for combating sexually-transmitted bacterial infections: liposomal azithromycin-in-chitosan hydrogel. Prof. Dr. Z. Vanić, University Zagreb/Croatia
  • Lipid nanovectors to use non-coding RNA oligonucleotides in glioblastoma in combination with standard therapy. Prof. Dr. G. de Rosa, University Frederico II Naples/Italy
  • Targeted liposomal antioxidant and anti-inflammatory therapy for liver ischemic reperfusion injury. Dr. L. Corvo, University Lisbon/Protugal